Advisory Committees

Antiviral Drugs Advisory Committee

Purpose

The Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of acquired immune deficiency syndrome, human immunodeficiency virus related illnesses, and other viral, fungal and mycobacterial infections, and makes appropriate recommendations to the Commissioner of Food and Drugs. 

Committee Membership

The Committee shall consist of a core of 13 voting members including the Chair. Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of clinical pharmacology, internal medicine, infectious diseases, microbiology, virology, psychiatry, statistics, epidemiology, ophthalmology, immunology, pediatrics, hematology, and related specialties. The core of voting members may include one technically qualified member, selected by the Commissioner or designee, who is identified with consumer interests and is recommended by either a consortium of consumer-oriented organizations or other interested persons. In addition to the voting members, the Committee may include one non-voting member who is identified with industry interests.

Contact Information

Jennifer Shepherd, RPh, Acting Designated Federal Officer
Division of Advisory Committee and Consultant Management
Office of Executive Programs
E-mail: AVAC@fda.hhs.gov

FDA Advisory Committee Information Line
1-800-741-8138
(301) 443-0572 (local number)
Please call the Information Line for up-to-date information on meetings.

Contact FDA

(301) 796-9001
Fax:(301) 847-8533
CDER Advisory Committee Staff

Food and Drug Administration

10903 New Hampshire Avenue

WO31-2417

Silver Spring, MD 20993-0002

Page Last Updated: 09/26/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.